Zabofloxacin

Last updated
Zabofloxacin
Zabofloxacin.svg
Names
Preferred IUPAC name
1-Cyclopropyl-6-fluoro-7-[(8E)-8-(methoxyimino)-2,6-diazaspiro[3.4]octan-6-yl]-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid
Other names
DW-224a
Identifiers
3D model (JSmol)
ChemSpider
PubChem CID
UNII
  • InChI=1S/C19H20FN5O4/c1-29-23-14-6-24(9-19(14)7-21-8-19)17-13(20)4-11-15(26)12(18(27)28)5-25(10-2-3-10)16(11)22-17/h4-5,10,21H,2-3,6-9H2,1H3,(H,27,28)/b23-14-
    Key: ZNPOCLHDJCAZAH-UCQKPKSFSA-N
  • InChI=1/C19H20FN5O4/c1-29-23-14-6-24(9-19(14)7-21-8-19)17-13(20)4-11-15(26)12(18(27)28)5-25(10-2-3-10)16(11)22-17/h4-5,10,21H,2-3,6-9H2,1H3,(H,27,28)/b23-14-
    Key: ZNPOCLHDJCAZAH-UCQKPKSFBL
  • Fc1c(nc2c(c1)C(=O)C(\C(=O)O)=C/N2C3CC3)N5C\C(=N\OC)C4(CNC4)C5
Properties
C19H20FN5O4
Molar mass 401.392
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).

Zabofloxacin (DW-224a) is an investigational fluoroquinolone antibiotic for multidrug-resistant infections due to Gram-positive bacteria. [1] [2] [3] [4] It also has activity against Neisseria gonorrhoeae including strains that are resistant to other quinolone antibiotics. [5]

Zabofloxacin was discovered by Dong Wha Pharmaceuticals and licensed to Pacific Beach BioSciences for development. [6]

A double-blind, three-arm clinical study of the drug began in March 2010. [7]

Related Research Articles

<span class="mw-page-title-main">Ciprofloxacin</span> Fluoroquinolones antibiotic

Ciprofloxacin is a fluoroquinolone antibiotic used to treat a number of bacterial infections. This includes bone and joint infections, intra abdominal infections, certain types of infectious diarrhea, respiratory tract infections, skin infections, typhoid fever, and urinary tract infections, among others. For some infections it is used in addition to other antibiotics. It can be taken by mouth, as eye drops, as ear drops, or intravenously.

<span class="mw-page-title-main">Ofloxacin</span> Antibiotic to treat bacterial infections

Ofloxacin is a quinolone antibiotic useful for the treatment of a number of bacterial infections. When taken by mouth or injection into a vein, these include pneumonia, cellulitis, urinary tract infections, prostatitis, plague, and certain types of infectious diarrhea. Other uses, along with other medications, include treating multidrug resistant tuberculosis. An eye drop may be used for a superficial bacterial infection of the eye and an ear drop may be used for otitis media when a hole in the ear drum is present.

<span class="mw-page-title-main">Norfloxacin</span> Chemical compound, antibiotic

Norfloxacin, sold under the brand name Noroxin among others, is an antibiotic that belongs to the class of fluoroquinolone antibiotics. It is used to treat urinary tract infections, gynecological infections, inflammation of the prostate gland, gonorrhea and bladder infection. Eye drops were approved for use in children older than one year of age.

<span class="mw-page-title-main">Seoul Institute of the Arts</span> University in Seoul, South Korea

Seoul Institute of the Arts is a prominent educational institution specializing in the Arts located in Ansan, Gyeonggi Province, South Korea. The school has nurtured many graduates who are actively working in art related fields within Korea as well as internationally. The Namsan campus in the heart of Seoul is used for presentation of arts productions and convergence with industry. The Ansan Campus opened in 2001 and is used for educational training, which aims to tear down barriers between disciplines, genres, and majors. The Institute continues to be a forerunner in globalization of Korean arts and creation of new forms of arts.

<span class="mw-page-title-main">Enoxacin</span>

Enoxacin is an oral broad-spectrum fluoroquinolone antibacterial agent used in the treatment of urinary tract infections and gonorrhea. Insomnia is a common adverse effect. It is no longer available in the United States.

<span class="mw-page-title-main">Netilmicin</span>

Netilmicin (1-N-ethylsisomicin) is a semisynthetic aminoglycoside antibiotic, and a derivative of sisomicin, produced by Micromonospora inyoensis. Aminoglycoside antibiotics have the ability to kill a wide variety of bacteria. Netilmicin is not absorbed from the gut and is therefore only given by injection or infusion. It is only used in the treatment of serious infections particularly those resistant to gentamicin.

<span class="mw-page-title-main">Sparfloxacin</span> Chemical to treat bacterial infections

Sparfloxacin is a fluoroquinolone antibiotic used in the treatment of bacterial infections. It has a controversial safety profile.

<span class="mw-page-title-main">Fleroxacin</span>

Fleroxacin is a quinolone antibiotic. It is sold under the brand names Quinodis and Megalocin.

<span class="mw-page-title-main">Prulifloxacin</span>

Prulifloxacin is an older synthetic antibiotic of the fluoroquinolone class undergoing clinical trials prior to a possible NDA submission to the U.S. Food and Drug Administration (FDA). It is a prodrug which is metabolized in the body to the active compound ulifloxacin. It was developed over two decades ago by Nippon Shinyaku Co. and was patented in Japan in 1987 and in the United States in 1989.

<span class="mw-page-title-main">Nadifloxacin</span>

Nadifloxacin is a topical fluoroquinolone antibiotic for the treatment of acne vulgaris. It is also used to treat bacterial skin infections.

<span class="mw-page-title-main">Clinafloxacin</span>

Clinafloxacin is an investigational fluoroquinolone antibiotic. Despite its promising antibiotic activity, the clinical development of clinafloxacin has been hampered by its risk for inducing serious side effects.

<span class="mw-page-title-main">Gonococcemia</span> Medical condition

Gonococcemia is a rare complication of mucosal Neisseria gonorrhoeae infection, or Gonorrhea, that occurs when the bacteria invade the bloodstream. It is characterized by fever, tender hemorrhagic pustules on the extremities or the trunk, migratory polyarthritis, and tenosynovitis. It also rarely leads to endocarditis and meningitis. This condition occurs in 0.5-3% of individuals with gonorrhea, and it usually presents 2–3 weeks after acquiring the infection. Risk factors include female sex, sexual promiscuity, and infection with resistant strains of Neisseria gonorrhoeae. This condition is treated with cephalosporin and fluoroquinolone antibiotics.

<span class="mw-page-title-main">South Korea at the 2006 Asian Games</span> Sporting event delegation

South Korea participated in the 2006 Asian Games in Doha, Qatar on 1–15 December 2006. South Korea ranked 2nd with 58 gold medals in this edition of the Asiad.

<span class="mw-page-title-main">Quinolone antibiotic</span> Class of antibacterial drugs, subgroup of quinolones

A quinolone antibiotic is a member of a large group of broad-spectrum bacteriocidals that share a bicyclic core structure related to the substance 4-quinolone. They are used in human and veterinary medicine to treat bacterial infections, as well as in animal husbandry, specifically poultry production.

<span class="mw-page-title-main">Antibiotic resistance in gonorrhea</span>

Neisseria gonorrhoeae, the bacterium that causes the sexually transmitted infection gonorrhea, has developed antibiotic resistance to many antibiotics. The bacteria was first identified in 1879.

<i>Jolly Widows</i> South Korean romance musical drama

Jolly Widows is a South Korean romance musical drama starring Shim Hye-jin, Lee Jong-soo, Park Hae-mi, Lee Chung-ah, Park Han-byul and Jo An. It aired on KBS1 from June 29, 2009 to January 29, 2010 on Mondays to Fridays at 20:25 for 155 episodes.

<span class="mw-page-title-main">Finafloxacin</span>

Finafloxacin (Xtoro) is a fluoroquinolone antibiotic. In the United States, it is approved by the Food and Drug Administration to treat acute otitis externa caused by the bacteria Pseudomonas aeruginosa and Staphylococcus aureus.

<i>Our Blues</i> 2022 South Korean television series

Our Blues is a 2022 South Korean television series starring Lee Byung-hun, Shin Min-a, Cha Seung-won, Lee Jung-eun, Uhm Jung-hwa, Han Ji-min, and Kim Woo-bin. The series revolves around the sweet and bitter lives of people at the end, climax, or beginning of life, and depicts their stories in an omnibus format against the backdrop of Jeju Island. It premiered on tvN on April 9, 2022, and aired every Saturday and Sunday at 21:10 (KST) with 20 episodes. It is available for streaming on Netflix in selected regions. It is also one of the highest-rated dramas in Korean cable television history.

References

  1. ↑ HyeKyung Han; Sung Eun Kim; Kwang-Hee Shin; Cheolhee Lim; Kyoung Soo Lim; Kyung-Sang Yu; Joo-Youn Cho (October 2013). "Comparison of pharmacokinetics between new quinolone antibiotics: the zabofloxacin hydrochloride capsule and the zabofloxacin aspartate tablet". Current Medical Research and Opinion. 29 (10): 1349–1355. doi:10.1185/03007995.2013.825591.
  2. ↑ Jong-Hwa Lee; Jung-Heun Ha; Dae-Hun Park; Dong-Rack Choi; Gye-Won Lee; Sung-Hoon Ahn & Choong-Yong Kim (2014). "Quantification Of Zabofloxacin In Rat Plasma Using Hplc-Uv Detector And Its Application To A Pharmacokinetic Study". Journal of Liquid Chromatography & Related Technologies. 37 (3): 311–320. doi:10.1080/10826076.2012.745137.
  3. ↑ Kim EJ, Shin WH, Kim KS, Han SS (Nov 2004). "Safety pharmacology of DW-224a, a novel fluoroquinolone antibiotic agent". Drug Chem Toxicol. 27 (4): 295–307. doi:10.1081/DCT-200039708. PMID   15573468.
  4. ↑ Park, Hee-Soo; Oh, Sang-Hun; Kim, Hye-Shin; Choi, Dong-Rack; Kwak, Jin-Hwan (2016-11-17). "Antimicrobial Activity of Zabofloxacin against Clinically Isolated Streptococcus pneumoniae". Molecules. 21 (11): 1562. doi:10.3390/molecules21111562. ISSN   1420-3049. PMC   6273590 . PMID   27869677.
  5. ↑ Jones RN, Biedenbach DJ, Ambrose PG, Wikler MA (2008). "Zabofloxacin (DW-224a) activity against Neisseria gonorrhoeae including quinolone-resistant strains". Diagn Microbiol Infect Dis. 62 (1): 110–112. doi:10.1016/j.diagmicrobio.2008.05.010. PMID   18620833.
  6. ↑ "Pacific Beach BioSciences and Dong Wha Pharmaceuticals Sign Exclusive License Agreement to Develop and Commercialize Zabofloxacin (PB-101, DW-224a)". GlobeNewswire. August 10, 2007.
  7. ↑ IASO Pharma Inc. (2012-05-04). "A Phase 2, Multi-Dose, Double-Blind, Double-Dummy, Active-Control, Randomized Study to Evaluate the Safety, Efficacy and Pharmacokinetic Profile of Two Dosing Regimens of Zabofloxacin for the Treatment of Community-Acquired Pneumonia of Moderate Severity".{{cite journal}}: Cite journal requires |journal= (help)
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.